Pancreatic Cancer Research

ResearcherUniversity Hospital HeidelbergActive in the last 2 years

Bruno Valentin Sinn

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1257-9799; OpenAlex author ID A5052578346, A5109128955. Sources: OpenAlex.

Their work

Papers
17 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
42
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: 3 papers · 2015: 2 papers · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper

Papers 17

  1. DNA methylation classifier to diagnose pancreatic ductal adenocarcinoma metastases from different anatomical sites. Co-author DOI 10.1186/s13148-024-01768-x↗
  2. Correction: Felsenstein M. et al. Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies? J. Clin. Med. 2022… Co-author DOI 10.3390/jcm12216947↗
  3. Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies? Co-author DOI 10.3390/jcm11092367↗
  4. Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. Co-author DOI 10.3389/fonc.2021.670396↗
  5. TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO… First author DOI 10.1158/1078-0432.ccr-19-3034↗
  6. Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-018-0093-y↗
  7. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2017.06.016↗
  8. P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment. Co-author DOI 10.1016/j.prp.2016.06.001↗
  9. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/nm.4038↗
  10. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treat… Co-author DOI 10.1016/j.ejca.2015.05.005↗
  11. Ataxia-telangiectasia-mutated protein kinase levels stratify patients with pancreatic adenocarcinoma into prognostic subgroups with loss being a strong indicat… Co-author DOI 10.1097/mpa.0000000000000248↗
  12. α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. Last author DOI 10.1038/bjc.2014.495↗
  13. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. First author DOI 10.1093/annonc/mdu084↗
  14. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000077↗
  15. Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study. Co-author DOI 10.1002/jso.23409↗
  16. High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/1471-2407-13-450↗
  17. High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer. Co-author DOI 10.1111/j.1365-2559.2012.04225.x↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Uwe Pelzer · 12 shared papers, 2013–2024 · strength 0.98
  2. Marcus Bahra · 14 shared papers, 2012–2024 · strength 0.81
  3. Jana Käthe Striefler · 11 shared papers, 2012–2021 · strength 0.60
  4. Carsten Denkert · 11 shared papers, 2012–2021 · strength 0.60
  5. Hanno B. Riess · 11 shared papers, 2012–2021 · strength 0.60
  6. Marianne Sinn · 10 shared papers, 2013–2021 · strength 0.58
  7. Helmut Oettle · 9 shared papers, 2013–2021 · strength 0.54
  8. Philipp Lohneis · 8 shared papers, 2014–2021 · strength 0.51
  9. Christian Benzing · 2 shared papers, 2022–2023 · strength 0.28
  10. Thomas Malinka · 2 shared papers, 2022–2023 · strength 0.28
  11. Mengwen Hu · 2 shared papers, 2022–2023 · strength 0.28
  12. Lea Timmermann · 2 shared papers, 2022–2023 · strength 0.28
  13. Matthäus Felsenstein · 2 shared papers, 2022–2023 · strength 0.28
  14. Uli Fehrenbach · 2 shared papers, 2022–2023 · strength 0.28
  15. Frederick Klauschen · 5 shared papers, 2012–2020 · strength 0.23
  16. Jens Stieler · 5 shared papers, 2013–2015 · strength 0.19
  17. Anja Jühling · 3 shared papers, 2016–2018 · strength 0.18
  18. Wilko Weichert · 5 shared papers, 2012–2016 · strength 0.18
  19. Albrecht Stenzinger · 5 shared papers, 2012–2016 · strength 0.18
  20. Mihnea Paul Dragomir · 1 shared paper, 2024 · strength 0.16
  21. Simon Schallenberg · 1 shared paper, 2024 · strength 0.16
  22. Teodor G. Calina · 1 shared paper, 2024 · strength 0.16
  23. Christopher Neumann · 1 shared paper, 2024 · strength 0.16
  24. Elena Grafenhorst · 1 shared paper, 2024 · strength 0.16
  25. George A. Călin · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.